PCWG4 Updates Prostate Cancer Trial Framework: PSMA PET, Molecular Biomarkers, and Patient-Centered Endpoints

PCWG4 revises prostate cancer trial design: integrates PSMA PET/CT for eligibility and response, redefines radiographic progression, and introduces 'no longer clinically benefitting' to guide treatment continuation beyond standard endpoints.

• PCWG4 is a guideline update (not a prospective study) summarizing recommendations for clinical trial design in prostate cancer after rapid advances in imaging, molecular diagnostics, and systemic therapies.
• Key change: formal integration of PSMA PET/CT into trial eligibility and response-assessment frameworks, with revised definitions of radiographic progression — specific numeric thresholds not reported in the source.
• Limitation: this is a recap/commentary of a consensus framework, not an independently validated empirical study; recommendations await prospective validation in trial cohorts.

RadPigeon summaries are original and for information only. They are not clinical advice.